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O-Linked b-N-acetyl glucosaminylation (O-GlcNAcylation) is a dynamic post-translational modification that occurs on serine 
and threonine residues of cytosolic and nuclear proteins in all cell types, including those involved in the cardiovascular system. 
O-GlcNAcylation is thought to act in a manner analogous to protein phosphorylation. O-GlcNAcylation rapidly cycles on/off 
proteins in a time scale similar to that for phosphorylation/dephosphorylation of proteins. Several studies indicate that O-
GlcNAc might induce nuclear localization of some transcription factors and may affect their DNA binding activities. However, at 
the cellular level, it has been shown that O-GlcNAc levels increase in response to stress and augmentation of this response sup-
presses cell survival. Increased levels of O-GlcNAc have been implicated as a pathogenic contributor to glucose toxicity and insu-
lin resistance, which are major hallmarks of type 2 diabetes and diabetes-related cardiovascular complications. Thus, O-GlcNAc 
and its metabolic functions are not yet well-understood; focusing on the role of O-GlcNAc in the cardiovascular system is a via-
ble target for biomedical investigation. In this review, we summarize our current understanding of the role of O-GlcNAc on the 
regulation of cell function and survival in the cardiovascular system.
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INTRODUCTION
The addition of O-linked b-N-acetyl glucosamine (O-GlcNAc) 
to the hydroxyl groups of serine and threonine residues on tar-
get proteins is a dynamic regulatory post-translational modifi-
cation of nuclear and cytosolic proteins [1]. It is involved in a 
wide range of biological processes such as nuclear transporta-
tion, transcription and translation, signal transduction, cyto-
skeletal reorganization, proteasomal degradation, and apopto-
sis [2,3]. In terms of abundance and protein distribution, O-
GlcNAc is often considered to be analogous to the phosphory-
lation of proteins [3]. Just as protein phosphorylation is regu-
lated by hundreds of kinases and phosphatases, O-GlcNAcyla-
tion is also tightly regulated by an enzymatic process. So far, 
only O-GlcNAc transferase (OGT) has been shown to catalyze 
the O-GlcNAcylation of proteins and one enzyme, N-acetyl-
glucosaminidase (O-GlcNAcase or OGA), catalyzes its removal 
[4,5]. The end-product of the hexosamine biosynthesis path-
way (HBP), uridine diphosphate-N-acetyl glucosamine (UDP-
GlcNAc), acts as a substrate for the O-GlcNAcylation of pro-
teins [6]. Approximately 2-5% of the total intracellular glucose 
enters the HBP and is ultimately converted to UDP-GlcNAc. 
The metabolism of glucose via the HBP is essential for the syn-
thesis of O-GlcNAc, which serves as a metabolic sensor that 
attenuates the cellular response to extracellular stimuli based 
on the energy state of the cell [7]. Several studies have demon-
strated that an acute increase in O-GlcNAc synthesis improves 
cell survival, while a sustained increase in O-GlcNAc levels has 
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been implicated as a pathogenic contributor to glucose toxicity 
and insulin resistance, major hallmarks of type 2 diabetes 
(T2D) and diabetes-related cardiovascular complications [8].
   In this review, we summarize our understanding of the role 
of O-GlcNAc in mediating both the adverse effects of diabetes 
as well as cellular protective mechanisms in the cardiovascular 
system.
CHARACTERIZATION OF O-GLCNACYLATION OF 
PROTEINS
Under normal conditions, two to five percent of the glucose 
taken up by cells is consumed by the HBP, and entrance of glu-
cose into the HBP is regulated by glutamine: fructose-6-phos-
phate amidotransferase (GFAT), which converts fructose-6-
phosphate to glucosamine-6-phosphate using glutamine as an 
amine donor. Glucosamine-6-phosphate is then metabolized 
via various intermediates, leading to the synthesis of UDP-
GlcNAc [9]. In addition, UDP-GlcNAc can be also increased 
by addition of exogenous glucosamine, which enters into cells 
via the glucose transporter system and is phosphorylated to 
glucosamine-6-phosphate by hexokinase, instead of the GFAT-
dependent HBP, leading to an increase in UDP-GlcNAc levels 
[10]. Using UDP-GlcNAc as a substrate, OGT catalyzes the 
transfer of GlcNAc via an O-linkage to specific serine and thre-
onine residues on target proteins [11]. OGT activity/O-glyco-
sylation is vital for life, confirmed by the observation that dele-
tion of the OGT gene was embryonic lethal [12]. The level of 
O-GlcNAcylation of nucleocytosolic proteins is also regulated 
by O-GlcNAcase, which catalyzes the removal of the sugar moi-
ety from the target proteins. Similar to the processes of phos-
phorylation/dephosphorylation, O-GlcNAcylation on the tar-
get proteins rapidly activates/deactivates the activities of pro-
teins involved in many aspects of cellular processing. At the same 
time, O-GlcNAcylated proteins can also be modified via phos-
phorylation, which modulates the functions of proteins by in-
fluencing protein-protein interactions and protein localization 
(Fig. 1) [13]. 
O-GLCNACYLATION, DIABETES, AND INSULIN 
RESISTANCE
Insulin resistance plays a major pathophysiological role in T2D 
and is tightly associated with major health problems, includ-
ing obesity, heart diseases, and dyslipidemia [14]. Marshall et 
al. [15] demonstrated that flux through the HBP is responsible 
for the development of insulin resistance and remarked that 
the development of insulin resistance requires glucose, insulin, 
and glutamine. The role of glutamine in the development of in-
sulin resistance has been found to occur via the regulation of 
GFAT, the rate limiting enzyme in the HBP [16]. Inhibition of 
GFAT with either azaserine or 6-diazo-5-oxo-norleucine abro-
gated the effects of hyperglycemia on the development of insu-
lin resistance [17]. Studies have shown that an increase in cel-
lular UDP-GlcNAc and O-GlcNAcylation levels on target pro-
teins due to high glucose and glucosamine treatments leads to 
oxidative stress and endoplasmic reticulum stress, which have 
been shown to cause chronic inflammation and insulin resis-
tance [18]. Blocking of the removal of O-GlcNAc using the 
OGA inhibitor, (2-acetamido-2-deoxy-D-glucopyranosylidene) 
amino-N-phenyl carbamate (PUGNAC) results in a decrease in 
insulin-response glucose uptake in 3T3-L1 adipocytes [19]. In 
insulin target cells, there appears to be a negative feedback regu-
lation of glucose transport via the flux of glucose through the 
HBP [20]. Insulin resistance and the corresponding decrease 
in glucose uptake are correlated with a defect in the transloca-
tion of the glucose transporter GLUT4 to the plasma membrane 
Fig. 1.  Interplay between O-GlcNAcylation and protein phos-
phorylation. (A) O-GlcNAc modification is strongly depen-
dent on the concentration of UDP-GlcNAc produced by the 
hexosamine biosynthetic pathway (HBP). OGT uses UDP-
GlcNAc as a substrate for GlcNAcylation on protein serine 
and threonine residues. O-GlcNAcase (OGA) removes the O-
GlcNAc moiety from O-GlcNAc-modified proteins. PUG-
NAC inhibits the activity of O-GlcNAcase. (B) O-GlcNAc 
modification is analogous to protein phosphorylation/de-
phosphorylation. Interplay between GlcNAcylation and phos-
phorylation can affect the activities or stabilities of the pro-
teins, and both processes can occur on the same protein at 
proximal sites. 
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[20]. Recent studies point to phosphatidylinositol-4, 5-bisphos-
phate (PIP2)-assisted remodeling of filamentous actin at the 
inner leaflet of the plasma membrane (cortical F-actin) as an-
other crucial step in insulin-stimulated GLUT4 translocation 
[21]. Bhonagiri et al. [22] showed that exposing 3T3-L1 adipo-
cytes to excess HBP flux leads to a reduction in PIP2 content in 
the plasma membrane, with a concomitant loss in cortical F-
actin, which affects insulin-induced GLUT4 translocation into 
the plasma membrane. In addition to the effects on GLUT4 
translocation, it has been reported that there are associations 
among HBP, insulin resistance, and impairment of Akt/PKB 
signaling [23]. Yang et al. [24] demonstrated that upon insulin 
stimulation, OGT is rapidly recruited from the nucleus to the 
plasma membrane by PIP3 through a region adjacent to the 
catalytic domain II at the carboxyl terminus of the OGT and 
demonstrated a potential mechanism by which Akt is presum-
ably able to be O-GlcNAcylated by the PIP3-recruited OGT. 
Based on these findings, impairment of O-GlcNAcylation reg-
ulation is reflected by a decrease in glucose uptake through in-
sulin resistance. 
O-GLCNACYLATION INDUCES VASCULAR 
DYSFUNCTION 
Hyperglycemia and insulin resistance are major causative fac-
tors for T2D and its vascular complications. High circulating 
glucose concentrations alter functions of the vascular endo-
thelial cells and the underlying smooth muscle cells [25]. Hy-
perglycemia can induce vascular complications via several dif-
ferent mechanisms, and one of the mechanisms is an increase 
of the HBP flux of glucose and O-GlcNAcylation of target pro-
tein [8]. Hyperglycemia-induced oxidative stress inhibits glyc-
eraldehydes 3-phosphate dehydrogenase, resulting in a de-
crease in glycolytic flux and an increased glucose flux in the 
HBP [26]. This increased flux of glucose may influence vascu-
lar remodeling as it can modulate the cell proliferation or cell 
death of different vascular cell types, such as pericytes, endo-
thelial cells, or smooth muscle cells.
O-GLCNACYLATION ON VASCULAR SMOOTH 
MUSCLE CELLS
Vascular smooth muscle cell (VSMC) dysfunction is a major 
risk factor of diabetic cardiovascular disease. VSMCs are high-
ly specialized cells whose principal functions are the contrac-
tion of blood vessels and the regulation of blood vessel tone-di-
ameter, which regulate the blood pressure and the blood flow, 
respectively. Under diabetic conditions, an increased flux of 
glucose through the HBP has been proposed to cause vascular 
disease. It has been observed that prolonged exposure to high 
glucose leads to the increase of GFAT expression in VSMCs 
[27], indicating that GFAT is possibly involved in the develop-
ment of the diabetic vascular complications. Inhibition of GFAT 
activity using 6-diazo-5-oxonorleucine decreases the hypergly-
cemia-induced tumor growth factor-alpha (TGF-α) expression 
in VSMCs, suggesting that the adverse effects of hyperglycemia 
in VSMCs are mediated by the HBP. Hall et al. [28] demonstrat-
ed that expressions of GLUT1 and GLUT4 are increased in the 
neointima of the aorta after balloon injury. Increased prolifer-
ation and decreased apoptosis of VSMCs provides a possible 
linkage with the increased risks of restenosis and atherosclero-
sis in patients with diabetes. Akimoto et al. [29] found that the 
pattern of O-GlcNAc modification of proteins changed when 
rat aortic smooth muscle cells (RASMCs) were cultured in me-
dium containing a high concentration of glucose. High glucose 
also elevates both the expression and activity of OGT [29]. In 
addition, high glucose and glucosamine also induced an increase 
in the expression of growth factors in RASMCs [30]. The effects 
of O-GlcNAc on cell growth and division may also contribute to 
the increase in VSMC proliferation seen in diabetes [31]. 
Treatment of VSMCs with high glucose increases the expres-
sions of TGF-α and basic fibroblast growth factor, leading to ab-
normal proliferation of smooth muscle cells, a characteristic as-
sociated with atherosclerotic lesions [30]. It has been reported 
that an elevated glucose concentration in VSMCs causes an in-
crease in the activity of protein kinase C (PKC), known to mod-
ulate the expression of several growth factors including TGF-α 
[32]. McClain et al. [30] also found that treatment of cells with 
phorbol ester to repress PKC and treatment of staurosporine 
to inhibit PKC did not affect the ability of glucose or glucos-
amine to activate the TGF-α promoter. Hattori et al. [33] found 
that hyperglycemia-induced activation of PKC was involved in 
the activation of TNFα-induced NF-kB, a transcription factor 
involved in the pathogenesis of atherosclerosis. Recently, Yang 
et al. [34] demonstrated that Thr
352 of the P65 subunit of NF-
kB was O-GlcNAcylated, which results in increases in its tran-
scriptional activity and half-life within the nuclei of VSMCs 
cultured under high glucose conditions. They also found that 
attenuation of O-GlcNAcylation by over-expression of OGA 
inhibits the high glucose-induced NF-kB activation in VSMCs. 
On the other hand, over-expression of OGT along with OGA 
inhibitor increases NF-kB transcriptional activity. These results 214
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suggest that O-GlcNAc modification of transcription factors 
presumably modulates their activities.
  As described above, excess glucose flux through the HBP re-
sults in elevated UDP-GlcNAc levels in VSMCs, which may have 
the capacity to modify and regulate vascular reactivity. Proteins 
with an important role in vascular function, such as endothelial 
nitric oxide synthase (eNOS), sarcoplasmic reticulum Ca
2+-
ATPase, phospholipase C, PKC, and phosphoinositide-3-kinase, 
are also targets for O-GlcNAcylation, suggesting that O-GlcNAc-
ylation may play a critical role in vascular reactivity [35]. In iso-
lated rat thoracic aortic rings, increasing O-GlcNAc formation 
via PUGNAC blunted vascular relaxation by acetylcholine and 
augmented vasoconstriction in response to phenyleprine [36]. 
In addition, treatment with ST060266, an OGT inhibitor, in-
hibits the U46619-induced blood vessel contraction which de-
pends on Rho kinase (RhoK) activity, suggesting that RhoK is 
also modified by GlcNAcylation (Kim DH and Jeoung NH, un-
published data). The contractile response of vascular smooth 
muscle is mediated through myosin light chain kinase (MLCK) 
and myosin light chain phosphatase (MLCP) activations, which 
are initiated by the Ca
2+-calmodulin interaction that causes 
phosphorylation of the myosin light chain (MLC) [37]. Clark 
et al. [38] demonstrated impaired calcium cycling via transcrip-
tional inhibition of sarcoplasmic Ca
2+-ATPase in OGT-over-
expressing cardiomyocytes. It was demonstrated that membrane 
depolarization promotes OGT activation, leading to induction 
of O-GlcNAcylation of total proteins, which can be reduced 
by inhibition of either voltage-gated Ca
2+ channels or Ca
2+-
calmodulin-dependent kinase IV (CAMIV), suggesting that 
OGT activity is regulated by Ca
2+ influx and CAMIV-depen-
dent phosphorylation. Interestingly, CAMIV has been shown 
to phosphorylate and activate OGT both in vivo and in vitro 
[39]. Smooth muscle cells also contain Ca
2+-independent mecha-
nisms to regulate contractibility. Removal of the phosphate 
group by MLCP results in inactivation of MLC and promotion 
of smooth muscle relaxation. MLCP consists of two subunits; 
one catalytic subunit of type 1 protein phosphatase (PP1cδ) 
and a non-catalytic subunit [40]. Recently Cheung et al. [41] 
found that MYPT1, a known targeting regulatory subunit of 
PP1cδ, is O-GlcNAcylated and also acts as a substrate for OGT. 
The substrate specificity of OGT is also regulated by MYPT1, 
which dephosphorylates OGT under different conditions. Based 
on the above findings, it is clear that O-GlcNAcylation on spe-
cific vascular proteins has an important role in the regulation 
vascular reactivity, and further research is necessary to deter-
mine the impact of O-GlcNAcylation on vascular reactivity.
O-GLCNACYLATION ON ENDOTHELIAL 
DYSFUNCTION
Endothelial cell dysfunction has emerged as a key component 
in the pathophysiology of cardiovascular abnormalities associ-
ated with diabetes [42]. Normal endothelial production of ni-
tric oxide by eNOS plays a pivotal role in the regulation of vas-
cular tone and remodeling, the inhibition of platelet aggrega-
tion and adhesion to the vascular wall, as well as the synthesis 
and secretion of extracellular matrix proteins, and proliferation 
of VSMCs [43]. Endothelial cells are sensitive to hyperglycemia 
because of their poor ability to regulate intracellular glucose 
[44]. In cultured bovine aortic endothelial cells, hyperglycemia 
caused an increase in mitochondrial superoxide production in 
association with an increase in O-GlcNAc on eNOS and a re-
ciprocal decrease in phosphorylation at Ser
1177, the site respon-
sible for activation of the enzyme [45]. Inhibition of GFAT by 
antisense oligonucleotides blocks the O-GlcNAcylation of 
eNOS, confirming the role of increased HBP flux of glucose. 
This O-GlcNAc-induced decrease in eNOS activity was asso-
ciated with increases in matrix metalloproteinase (MMP) ac-
tivity and expression combined with decreased tissue inhibi-
tion of metalloproteinase (TIMP) expression [46]. An imbal-
ance between MMPs and TIMPs has been implicated in athero-
sclerosis-related complications in diabetes [46]. Du et al. [47] 
demonstrated that hyperglycemia-induced expression of plas-
minogen activator inhibitor-1 (PAI-1) in endothelial cells was 
associated with an increase in O-GlcNAc levels on Sp1, which 
increases expression of TGF-1b, a potent inducer of extracel-
lular matrix protein synthesis, leading to proliferation of VSMCs 
and fibroblasts. High glucose also induces O-GlcNAc modifi-
cation of Sp3 and up-regulates angiopoietin-2 gene expression 
in the microvascular system [48]. This leads to the induction 
of ICAM-1 and VCAM-1 expressions and sensitization of mi-
crovascular endothelial cells to the proinflammatory effects of 
TNFα. Increased O-GlcNAcylation of Sp1 and Sp3 also regu-
lates the endothelial cell-specific expression of vascular endo-
thelium growth factor receptor [49]. These observations sug-
gest that chronically elevated O-GlcNAc level represents a com-
mon mechanism underlying the adverse effects of hyperglyce-
mia. The vascular effects of HBP/O-GlcNAc signaling are just 
beginning to be understood, and a more direct link between 
increased O-GlcNAc levels and vascular dysfunction remains 
to be discovered (Fig. 2). 215
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O-GLCNACYLATION AND CARDIOVASCULAR 
PROTECTION
Many studies have shown that a loss of control of the dynam-
ics of O-GlcNAcylation interferes with the normal progress of 
fundamental events and may be implicated in the appearance 
of pathological states. However, since OGT is essential for cell 
viability and is highly conserved from an evolutionary perspec-
tive, its presence has to convey some survival advantage to cells 
and organisms [12]. It has been supported by a number of 
studies demonstrating that an acute increase in O-GlcNAc syn-
thesis improves tolerance to a variety of stressful stimuli and 
increases cell survival [50,51]. When the O-GlcNAc response 
was inhibited by decreased OGT expression, cell viability also 
decreased, whereas augmentation of O-GlcNAc levels with 
PUGNAC increased cell survival [52]. Glucose uptake in cells 
has been linked to the capacity of cells to respond and survive 
deleterious cellular conditions. Even though the sustained hy-
perglycemia in T2D is clearly associated with the adverse ef-
fects at the cellular level, the acute increases in circulating glu-
cose level and of glucose utilization in tissues have beneficial 
effects on cell survival. It has been reported that increased glu-
cose utilization protects against a wide range of injuries like 
trauma, sepsis, shock, cardiac surgery, and myocardial infarc-
tion [50]. During acute heat stress conditions, an increase in 
O-GlcNAc levels enhances cell survival, whereas inhibition of 
GFAT decreases O-GlcNAc levels in the cells, leading to an in-
crease in cell death [51]. Increasing the O-GlcNAc level results 
in cells that are more thermo-tolerant, which results in an in-
crease in the expressions of heat shock protein 40 (HSP40) and 
HSP70 induced by the O-GlcNAc signaling pathway [53].
  Acute activation of O-GlcNAc formation inhibits acute in-
flammatory and neointimal responses to endoluminal vascu-
lar injury in vivo [54]. Further, increases in O-GlcNAc-modi-
fied proteins decrease the expressions of inflammatory media-
tors and the infiltration of leukocytes at the injured endolumi-
nal carotid artery. Since augmentation of O-GlcNAc levels at-
tenuates the activation of inflammatory mediators in acute car-
diovascular injury, it is possible that an increased O-GlcNAc 
level in diabetes may be beneficial for its ability to attenuate the 
proinflammatory response. Glucosamine treatment during re-
suscitation improved cardiac function by reducing the trauma-
hemorrhage-induced ICAM-1 expression, NF-kB expression, 
and NF-kB DNA binding activity in the heart [55], suggesting 
that acutely increased O-GlcNAc level may reduce the NF-kB-
mediated inflammation.
  In isolated neonatal cardiomyocytes, hypoxia-reperfusion 
causes a transient increase in O-GlcNAc level and improves cell 
viability. Treatment of neonatal cardiomyocytes with glucos-
amine, hyperglycemia, or PUGNAC significantly increases O-
GlcNAc level, improves cell viability, and decreases necrosis and 
apoptosis [56]. Schaffer et al. [57] reported that high glucose 
significantly reduces hypoxia-induced apoptosis and necrosis 
in isolated cardiomyocytes via decreased Ca
2+ overload. Inter-
estingly, cardiac mitochondria isolated from PUGNAC-treated 
mice and also OGT-over-expressing neonatal rat cardiomyo-
cytes are resistant to Ca
2+ induced mitochondrial membrane 
transition pore (mPTP) formation, a critical step in the initia-
tion of apoptosis and cell death [58]. Recently, Champattana-
chai et al. [59] found that glucosamine, OGT over-expression, 
and O-GlcNAcase inhibition protect neonatal cardiomyocytes 
from ischemia-reperfusion injury via an increased level of mi-
tochondrial bcl-2, a key regulatory protein for cell survival. A 
glucosamine-induced increase in bcl-2 inhibits mPTP open-
ing via direct interaction with voltage-dependent anion chan-
nel 1α, one of the putative components of mPTP (Fig. 3). 
  Thus, acute activation of metabolic pathways leading to an 
HBP and Vascular dysfunction
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Fig. 2.  A fraction (2-5%) of the glucose entering a cell is di-
rected into the hexosamine biosynthesis pathway (HBP) path-
way. GFAT (glutamine: fructose-6-phosphate amidotransfer-
ase) uses glutamine to convert fructose-6-phosphate into glu-
cosamine-6-phosphate, which is then used for the synthesis of 
UDP-GlcNAc in the cell. Activation of the HBP pathway acts 
through Sp1 sites to increase plasminogen activator inhibi-
tor-1 (PAI-1)  and tumor growth factor-alpha expressions. At 
the same time, O-GlcNAc modification of endothelial nitric 
oxide synthase (eNOS) decreases its activity and nitric oxide 
(NO) production.216
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increase in O-GlcNAc level is an endogenous stress-activated 
response, and augmentation of this response improves short 
term protection in the cardiovascular system. Induction of pro-
survival factors such as HSP or attenuation of the inflammato-
ry response improves long term cardiovascular protection. Fur-
ther studies on the function of O-GlcNAc-modified proteins 
in complex signaling networks will provide answers surround-
ing cell survival in response to stress. 
CONCLUSIONS
In this review, we summarized the data supporting the benefi-
cial effects related to acute increases in O-GlcNAc level, as well 
as the adverse effects produced by chronic activation. This sug-
gests that the initial response to an acute stress induces protec-
tive processes and improves survival; as the load increases, the 
continued activation of the pathway results in the development 
of pathophysiology. Thus, altering the O-GlcNAc levels in vas-
cular tissues may represent a novel therapeutic approach for the 
treatment of diabetic cardiovascular disease.
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